Super 1 T-cell receptor therapy (Guangzhou FineImmune Biotechnology)

N/A

Report date: 2025/07/04 16:55:16

Base Information

Drug NameSuper 1 T-cell receptor therapy (Guangzhou FineImmune Biotechnology)
Drug Alias NameSuper1 TCR-TNY-ESO-1 TCR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionCancer/testis antigen 1 modulatorsT lymphocytes stimulants
TargetsCancer/testis antigen 1
Therapy Area/IndicationsSolid tumoursLung NeoplasmsMelanoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Fineimmune Biotechnology
China Registration ClassN/A

Develop Information

Active CompaniesImmunotech Applied Science LtdGuangzhou Fineimmune Biotechnology
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsMelanoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A